Small Interfering RNA for Gliomas Treatment: Overcoming Hurdles in Delivery
Gliomas are central nervous system tumors originating from glial cells, whose incidence and mortality rise in coming years. The current treatment of gliomas is surgery combined with chemotherapy or radiotherapy. However, developing therapeutic resistance is one of the significant challenges. Recent...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-07-01
|
| Series: | Frontiers in Cell and Developmental Biology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcell.2022.824299/full |
| _version_ | 1818535854990163968 |
|---|---|
| author | Xin-Qi Teng Xin-Qi Teng Xin-Qi Teng Jian Qu Guo-Hua Li Hai-Hui Zhuang Qiang Qu Qiang Qu |
| author_facet | Xin-Qi Teng Xin-Qi Teng Xin-Qi Teng Jian Qu Guo-Hua Li Hai-Hui Zhuang Qiang Qu Qiang Qu |
| author_sort | Xin-Qi Teng |
| collection | DOAJ |
| description | Gliomas are central nervous system tumors originating from glial cells, whose incidence and mortality rise in coming years. The current treatment of gliomas is surgery combined with chemotherapy or radiotherapy. However, developing therapeutic resistance is one of the significant challenges. Recent research suggested that small interfering RNA (siRNA) has excellent potential as a therapeutic to silence genes that are significantly involved in the manipulation of gliomas’ malignant phenotypes, including proliferation, invasion, metastasis, therapy resistance, and immune escape. However, it is challenging to deliver the naked siRNA to the action site in the cells of target tissues. Therefore, it is urgent to develop delivery strategies to transport siRNA to achieve the optimal silencing effect of the target gene. However, there is no systematic discussion about siRNAs’ clinical potential and delivery strategies in gliomas. This review mainly discusses siRNAs’ delivery strategies, especially nanotechnology-based delivery systems, as a potential glioma therapy. Moreover, we envisage the future orientation and challenges in translating these findings into clinical applications. |
| first_indexed | 2024-12-11T18:30:29Z |
| format | Article |
| id | doaj.art-5bc3e8ac77f745619cdbbce05d2a7238 |
| institution | Directory Open Access Journal |
| issn | 2296-634X |
| language | English |
| last_indexed | 2024-12-11T18:30:29Z |
| publishDate | 2022-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cell and Developmental Biology |
| spelling | doaj.art-5bc3e8ac77f745619cdbbce05d2a72382022-12-22T00:54:56ZengFrontiers Media S.A.Frontiers in Cell and Developmental Biology2296-634X2022-07-011010.3389/fcell.2022.824299824299Small Interfering RNA for Gliomas Treatment: Overcoming Hurdles in DeliveryXin-Qi Teng0Xin-Qi Teng1Xin-Qi Teng2Jian Qu3Guo-Hua Li4Hai-Hui Zhuang5Qiang Qu6Qiang Qu7Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, ChinaNational Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, ChinaDepartment of Pharmacy, The Second Xiangya Hospital, Institute of Clinical Pharmacy, Central South University, Changsha, ChinaDepartment of Pharmacy, The Second Xiangya Hospital, Institute of Clinical Pharmacy, Central South University, Changsha, ChinaDepartment of Pharmacy, The Second Xiangya Hospital, Institute of Clinical Pharmacy, Central South University, Changsha, ChinaDepartment of Pharmacy, The Second Xiangya Hospital, Institute of Clinical Pharmacy, Central South University, Changsha, ChinaDepartment of Pharmacy, Xiangya Hospital, Central South University, Changsha, ChinaNational Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, ChinaGliomas are central nervous system tumors originating from glial cells, whose incidence and mortality rise in coming years. The current treatment of gliomas is surgery combined with chemotherapy or radiotherapy. However, developing therapeutic resistance is one of the significant challenges. Recent research suggested that small interfering RNA (siRNA) has excellent potential as a therapeutic to silence genes that are significantly involved in the manipulation of gliomas’ malignant phenotypes, including proliferation, invasion, metastasis, therapy resistance, and immune escape. However, it is challenging to deliver the naked siRNA to the action site in the cells of target tissues. Therefore, it is urgent to develop delivery strategies to transport siRNA to achieve the optimal silencing effect of the target gene. However, there is no systematic discussion about siRNAs’ clinical potential and delivery strategies in gliomas. This review mainly discusses siRNAs’ delivery strategies, especially nanotechnology-based delivery systems, as a potential glioma therapy. Moreover, we envisage the future orientation and challenges in translating these findings into clinical applications.https://www.frontiersin.org/articles/10.3389/fcell.2022.824299/fullgliomasglioblastomasiRNAdeliverynanoparticlestherapy-resistance |
| spellingShingle | Xin-Qi Teng Xin-Qi Teng Xin-Qi Teng Jian Qu Guo-Hua Li Hai-Hui Zhuang Qiang Qu Qiang Qu Small Interfering RNA for Gliomas Treatment: Overcoming Hurdles in Delivery Frontiers in Cell and Developmental Biology gliomas glioblastoma siRNA delivery nanoparticles therapy-resistance |
| title | Small Interfering RNA for Gliomas Treatment: Overcoming Hurdles in Delivery |
| title_full | Small Interfering RNA for Gliomas Treatment: Overcoming Hurdles in Delivery |
| title_fullStr | Small Interfering RNA for Gliomas Treatment: Overcoming Hurdles in Delivery |
| title_full_unstemmed | Small Interfering RNA for Gliomas Treatment: Overcoming Hurdles in Delivery |
| title_short | Small Interfering RNA for Gliomas Treatment: Overcoming Hurdles in Delivery |
| title_sort | small interfering rna for gliomas treatment overcoming hurdles in delivery |
| topic | gliomas glioblastoma siRNA delivery nanoparticles therapy-resistance |
| url | https://www.frontiersin.org/articles/10.3389/fcell.2022.824299/full |
| work_keys_str_mv | AT xinqiteng smallinterferingrnaforgliomastreatmentovercominghurdlesindelivery AT xinqiteng smallinterferingrnaforgliomastreatmentovercominghurdlesindelivery AT xinqiteng smallinterferingrnaforgliomastreatmentovercominghurdlesindelivery AT jianqu smallinterferingrnaforgliomastreatmentovercominghurdlesindelivery AT guohuali smallinterferingrnaforgliomastreatmentovercominghurdlesindelivery AT haihuizhuang smallinterferingrnaforgliomastreatmentovercominghurdlesindelivery AT qiangqu smallinterferingrnaforgliomastreatmentovercominghurdlesindelivery AT qiangqu smallinterferingrnaforgliomastreatmentovercominghurdlesindelivery |